{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:01:06Z","timestamp":1787029266412,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EGIS Polska","award":["0123\/EG"],"award-info":[{"award-number":["0123\/EG"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>New clinical reports have recently been published on tofisopam\u2014an anxiolytic drug currently registered as a benzodiazepine\u2014after a long break in this research area. Neurobiological studies concerning its properties, which differ from those of benzodiazepines, are underway. The analyses presented in this study aimed to compare the effects of tofisopam, diazepam, and a placebo in the treatment of anxiety symptoms. A total of 66 outpatients (43 women and 23 men) with generalized anxiety disorder aged 19 to 74 years (M = 41.4; SD = 13.2) were randomized in three groups receiving (1) tofisopam (50 mg three times a day), (2) diazepam (5 mg three times a day), or (3) a placebo for 2 weeks. Then, throughout a 2-week washout period, the patients were monitored for withdrawal symptoms. During the last 2 weeks, the effects of tofisopam (50 mg three times a day) and diazepam (5 mg three times a day) were compared (crossover design). The mean improvement on the Hamilton Anxiety Rating Scale was significantly higher in both the tofisopam and diazepam groups compared to the placebo group. There were no significant differences between the effects of diazepam and tofisopam, whereas adverse effects and withdrawal symptoms occurred less frequently in the tofisopam group. Tofisopam did not impair cognitive abilities, and related withdrawal symptoms resembled those of the placebo. If larger future studies corroborate these findings, tofisopam should be classified as a homophtalazine.<\/jats:p>","DOI":"10.3390\/ph17010140","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T05:42:31Z","timestamp":1705902151000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Comparison of the Anxiolytic Properties of Tofisopam and Diazepam: A Double-Blind, Randomized, Crossover, Placebo-Controlled Pilot Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-5494","authenticated-orcid":false,"given":"Andrzej","family":"Kokoszka","sequence":"first","affiliation":[{"name":"II Department of Psychiatry, Medical University of Warsaw, 8 Kondratowicza Street, 03-242 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"ref_1","first-page":"154","article-title":"Current update on evidence-based literature of tofisopam","volume":"17","author":"Srivastava","year":"2014","journal-title":"Delhi Psychiatry J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0301-0082(99)00020-9","article-title":"Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia","volume":"60","author":"Horvath","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00542458","article-title":"A comparison of the psychotropic profiles of tofisopam and diazepam","volume":"22","author":"Bond","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_4","first-page":"1","article-title":"Action du tofisopam sur niveaub de vigilance ergonomique. Son interaction avec les effect de l\u2019alcohol. Etude de pharmacologie clinique","volume":"49","author":"Demange","year":"1976","journal-title":"Rev. Int. Serv. Sant\u00e9 Arm\u00e9es Terre Mer L\u2019air"},{"key":"ref_5","first-page":"143","article-title":"The effect of Grandaxin on lorry drivers","volume":"23","author":"Gerevich","year":"1975","journal-title":"Ther. Hung."},{"key":"ref_6","first-page":"309","article-title":"Tofizopam: A benzodiazepine derivative without sedative effect","volume":"20","author":"Kanto","year":"1982","journal-title":"Int. Clin. Pharmac. Ther. Toxic"},{"key":"ref_7","first-page":"541","article-title":"The effect of tofisopam on psychic performance in persons with more average anxiety: A controlled experimental trial","volume":"35","author":"Maier","year":"1984","journal-title":"Curr. Ther. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00427652","article-title":"Tofisopam, a novel 3,4-benzodiazepine: Multiple dose effects and psychomotor skills and memory. Comparison with diazepam and interactions with ethanol","volume":"69","author":"Sepalla","year":"1980","journal-title":"Psychopharmacology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0149-7634(86)90026-6","article-title":"Is tofisopam an atypical anxiolytic?","volume":"10","author":"Pellow","year":"1986","journal-title":"Neurosci. Behav. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0031-6989(82)80062-3","article-title":"Tofisopam selectively increases the affinity of benzodiazepine binding sites for [3H] flunitrazepam but not [3H]-\u03b2-carboline-3-carboxilic and ethyl ester","volume":"14","author":"Saano","year":"1982","journal-title":"Pharmac. Res. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0091-3057(82)90094-6","article-title":"Tofisopam modulates the affinity of benzodiazepine receptors in the rat brain","volume":"17","author":"Saano","year":"1982","journal-title":"Pharmac. Biochem. Behav."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00310505","article-title":"Intrinsic actions of benzodiazepine receptor antagonists Ro 15-1788","volume":"88","author":"File","year":"1986","journal-title":"Psychopharmacology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00518477","article-title":"Brain levels of tofisopam in the rat and relationship with benzodiazepine receptors","volume":"321","author":"Menninin","year":"1982","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"ref_14","first-page":"21","article-title":"Tofizopam\u2014Przegl\u0105dpi\u015bmiennictwa (Tofisopam\u2014Review of literature)","volume":"4","author":"Kokoszka","year":"2001","journal-title":"Wiadomo\u015bci Psychiatryczne"},{"key":"ref_15","first-page":"53","article-title":"Por\u00f3wnanie skuteczno\u015bci i bezpiecze\u0144stwa lek\u00f3w w zaburzeniach l\u0119kowych uog\u00f3lnionych. Wie-loo\u015brodkowa randomizowana podw\u00f3jnie \u015blepa pr\u00f3ba por\u00f3wnuj\u0105ca dzia\u0142anie tofizopamu, hydroksyzyny i diazepamu. A multicentre double-blind study investigating the anxiolytic efficacy of diazepam, hydroxyzine and tofisopam in patients with generalized anxiety","volume":"3","author":"Rzewuska","year":"2003","journal-title":"Farmakoter. W Psychiatr. I Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2036.2007.03566.x","article-title":"Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome","volume":"27","author":"Raudibaugh","year":"2008","journal-title":"Clin. Trial Aliment. Pharmacol. Ther."},{"key":"ref_18","first-page":"S368","article-title":"Tofisopam as an alternative intervention in organic catatonia: An open label study","volume":"61","author":"Ravan","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0253717621994285","article-title":"Role of Tofisopam in Post COVID Neuropsychiatric Sequelae: A Case Series","volume":"43","author":"Pattnaik","year":"2021","journal-title":"Indian J. Psychol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00702-010-0507-3","article-title":"The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis","volume":"117","author":"Rundfeldt","year":"2010","journal-title":"J. Neural. Transm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"172858","DOI":"10.1016\/j.pbb.2020.172858","article-title":"Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats","volume":"190","author":"Can","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"New depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guy, W. (1976). Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology, Revised, DHEW Publ. No. ADM 76-338.","DOI":"10.1037\/e591322011-001"},{"key":"ref_24","first-page":"945","article-title":"Kwestionariusz objawowy S-II [S-II symptom questionnaire]","volume":"34","author":"Aleksandrowicz","year":"2000","journal-title":"Psychiatr. Pol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_26","unstructured":"Gelder, M., Gath, D., and Mayou, R. (1993). Oxford Textbook of Psychiatry, Oxford University Press. [2nd ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","article-title":"The Mini In-ternational Neuropsychiatric Interview, (M.I.N.I.), a short diagnostic interview: Reliability and validity according to the CIDI","volume":"12","author":"Lecrubier","year":"1997","journal-title":"Eur. Psychiatry"},{"key":"ref_28","unstructured":"Masiak, M., and Przychoda, J.M.I.N.I. (1998). Mini International Neuropsychiatric Interview. Polish Version 5.0.0, Katedra i Klinika Psychiatrii Akademii Medycznej."},{"key":"ref_29","first-page":"S366","article-title":"A double-blind, placebo-controlled comparison of tofisopam and diazepam in the treat-ment of generalized anxiety disorder","volume":"7","author":"Kokoszka","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/S0924-977X(05)80331-1","article-title":"The profile of anti-anxiety action of tofisopam in the treatment of generalized anxiety disorder","volume":"15","author":"Kokoszka","year":"2005","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:06Z","timestamp":1760104026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ph17010140"],"URL":"https:\/\/doi.org\/10.3390\/ph17010140","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}